Haley Altamura

846 total citations
8 papers, 408 citations indexed

About

Haley Altamura is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Haley Altamura has authored 8 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 7 papers in Genetics and 5 papers in Rheumatology. Recurrent topics in Haley Altamura's work include Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Eosinophilic Disorders and Syndromes (5 papers). Haley Altamura is often cited by papers focused on Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Eosinophilic Disorders and Syndromes (5 papers). Haley Altamura collaborates with scholars based in Australia, South Korea and United States. Haley Altamura's co-authors include Timothy P. Hughes, Susan Branford, David T Yeung, David M. Ross, Bronte A. Jamison, Alexandra L. Yeoman, Stuart Phillis, John F. Seymour, Wendy T Parker and Jodi Braley and has published in prestigious journals such as Blood and Leukemia.

In The Last Decade

Haley Altamura

8 papers receiving 406 citations

Peers

Countries citing papers authored by Haley Altamura

Since Specialization

Citations

This map shows the geographic impact of Haley Altamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haley Altamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haley Altamura more than expected).

Fields of papers citing papers by Haley Altamura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haley Altamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haley Altamura. The network helps show where Haley Altamura may publish in the future.

Co-authorship network of co-authors of Haley Altamura

This figure shows the co-authorship network connecting the top 25 collaborators of Haley Altamura. A scholar is included among the top collaborators of Haley Altamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haley Altamura. Haley Altamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy 2023 ·Blood ·Ilaria S. Pagani, Naranie Shanmuganathan, Phuong Dang, Verity A Saunders, Randall Grose, Chung Hoow Kok, (unknown), (unknown), Jodi Braley, Haley Altamura, David T Yeung, Susan Branford, Agnes S. M. Yong, Timothy P. Hughes, David M. Ross	5
2	Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia 2020 ·Blood ·Naranie Shanmuganathan, Ilaria S. Pagani, David M. Ross, Sa-Hee Park, Agnes S. M. Yong, Jodi Braley, Haley Altamura, Devendra Hiwase, David T Yeung, Dong‐Wook Kim, Susan Branford, Timothy P. Hughes	46
3	Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission 2019 ·Leukemia ·Ilaria S. Pagani, Phuong Dang, Verity A Saunders, Randall Grose, Naranie Shanmuganathan, Chung Hoow Kok, (unknown), (unknown), (unknown), (unknown), Jodi Braley, Haley Altamura, David T Yeung, Susan Branford, Agnes S. M. Yong, Deborah L. White, Timothy P. Hughes, David M. Ross	31
4	The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib 2016 ·Blood ·Wendy T Parker, David T Yeung, Alexandra L. Yeoman, Haley Altamura, Bronte A. Jamison, (unknown), John Hodgson, Stephanie Lustgarten, Victor M. Rivera, Timothy P. Hughes, Susan Branford	50
5	Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline 2014 ·Blood ·Susan Branford, David T Yeung, Wendy T Parker, Nicola D. Roberts, Leanne Purins, Jodi Braley, Haley Altamura, Alexandra L. Yeoman, (unknown), Bronte A. Jamison, Stuart Phillis, (unknown), (unknown), Linda Fletcher, John F. Seymour, Andrew Grigg, David M. Ross, Timothy P. Hughes	136
6	Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months 2013 ·Blood ·Nicola D. Roberts, (unknown), (unknown), Haley Altamura, Wendy T Parker, Timothy P. Hughes	14
7	Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML 2013 ·Blood ·Susan Branford, David T Yeung, David M. Ross, (unknown), (unknown), Haley Altamura, Alexandra L. Yeoman, (unknown), Bronte A. Jamison, Stuart Phillis, (unknown), Nancy Briggs, Mark Hertzberg, John F. Seymour, John Reynolds, Timothy P. Hughes	121
8	Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML 2012 ·Blood ·Susan Branford, David M. Ross, (unknown), (unknown), Haley Altamura, Alexandra L. Yeoman, (unknown), Stuart Phillis, Bronte A. Jamison, (unknown), (unknown), Timothy P. Hughes	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact